Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 5, 2008, Pages 347-352

  Shimasaki, Noriko ^a   Mori, Tetsuya ^a,b   Torii, Chiharu ^a   Sato, Reiko ^a   Shimada, Hiroyuki ^a   Tanigawara, Yusuke ^a   Kosaki, Kenjiro ^a   Takahashi, Takao ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Maintenance chemotherapy; Methylenetetrahydrofolate reductase (MTHFR); Polymorphism; Reduced folate carrier 1 (RFC1)

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMINOTRANSFERASE; GENOMIC DNA; MERCAPTOPURINE; METHOTREXATE; REDUCED FOLATE CARRIER; REDUCED FOLATE CARRIER 1; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLELE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFECTION; LYMPHOBLASTOMA; MAINTENANCE THERAPY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC AGENTS; CARBON-NITROGEN LIGASES; CHILD; CHILD, PRESCHOOL; GENOTYPE; HUMANS; METHOTREXATE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REPLICATION PROTEIN C;

EID: 43149111567     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318165b25d     Document Type: Article

References (23)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
2. Pui CH, Relling MV, Evans WE. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002;15:741-756.
3. Shimasaki N, Mori T, Samejima H, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2006;28:64-68.
4. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology. 2000;61:136-146.
5. Udaka T, Torii C, Takahashi D, et al. Comprehensive screening of the thiopurine methyltransferase polymorphisms by denaturing high-performance liquid chromatography. Genet Test. 2005;9:85-92.
6. Ando M, Ando Y, Hasegawa Y, et al. Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukaemia. Pharmacogenetics. 2001;11:269-273.
7. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001-2008.
8. Ueland PM, Hustad S, Schneede J, et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001;22:195-201.
9. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
10. Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98:231-234.
11. Chiusolo P, Reddiconto G, Casorelli I, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol. 2002;13:1915-1918.
12. Whetstine JR, Gifford AJ, Witt T, et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res. 2001;7:3416-3422.
13. Laverdiere C, Chiasson S, Costea I, et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood. 2002;100:3832-3834.
14. Schmiegelow K, Pulczynska MK. White-cell counts in childhood acute lymphoblastic leukemia. Eur J Haematol. 1990;44:72-74.
15. Tsuchida M, Ikuta K, Hanada R, et al. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995. Leukemia. 2000;14:2295-2306.
16. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol. 2000;18:1508-1516.
17. Japan Clinical Oncology Group. Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines. Int J Clin Oncol. 2004;9(suppl 3):1-82.
18. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
19. Hanley JA, Negassa A, Edwardes MD, et al. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157:364-375.
20. Weisberg IS, Jacques PF, Selhub J, et al. The 1298A→C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis. 2001;156:409-415.
21. Tiftikci A, Ozdemir A, Tarcin O, et al. Influence of serum folic acid levels on plasma homocysteine concentrations in patients with rheumatoid arthritis. Rheumatol Int. 2006;26:191-194.
22. Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol. 1998;25:36-43.
23. Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80G-> A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab. 2000;70:310-315.